Emergent Biosolutions (EBS) 17.39 0.03

Emergent Biosolutions
(EBS) 17.39 0.03

Last Trade:	17.38	Day Range:	17.36 - 17.60
Trade Time:	11:02AM	52wk Range:	14.90 - 25.24
Prev. Close:	17.35	Market Cap:	624.86M
Open:	17.48	Div Yield:	0
Volume:	32926	PE:
EPS:	0.61

The Latest On EBS

Weekly Traders Homework: Frustrated Bears 1/29/12 8:15pm

Emergent BioSolutions Subsidiary Announces Contract Modification 1/17/12 2:16pm

Financial Breakfast: Morning News Summary for January 9, 2012 1/9/12 7:26am

Emergent BioSolutions Expects 2012 Revs $280-$300M vs $309M Est 1/9/12 7:02am

A Peek Into The Market Before The Trading Starts 12/28/11 7:59am

Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott 12/28/11 7:00am

Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia 12/28/11 7:00am

Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO 12/21/11 2:00pm

European morning wrap: Risk off, innit bro 12/12/11 7:25am

Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia 12/1/11 7:04am

WABCO Marks Another Industry First for Advanced Safety Technology in China as Part of Contract With Yutong, 11/29/11 7:02am

Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis 11/17/11 6:53am

Weekly Traders Homework: Frustrated Bears 1/29/12

Emergent BioSolutions Subsidiary Announces Contract Modification 1/17/12

Financial Breakfast: Morning News Summary for January 9, 2012 1/9/12

Emergent BioSolutions Expects 2012 Revs $280-$300M vs $309M Est 1/9/12

A Peek Into The Market Before The Trading Starts 12/28/11

Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott 12/28/11

Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia 12/28/11

Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO 12/21/11

European morning wrap: Risk off, innit bro 12/12/11

Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia 12/1/11

WABCO Marks Another Industry First for Advanced Safety Technology in China as Part of Contract With Yutong, 11/29/11

Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis 11/17/11

Weekly Traders Homework: Frustrated Bears 1/29/12

Financial Breakfast: Morning News Summary for January 9, 2012 1/9/12

Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROE 10/24/11

Top Percentage Gainers and Losers as of 12pm 5/09/11 (SCEI, FFHL ROSE, SMI, DTG, HTZ, SYY, CERS, LFT, ZRAN, OXGN, MOBI, GKK, EBS, TSN) 5/9/11

Biotech/ Biodefense Sector Trading Alert 5/5/11

Emergent BioSolutions Hits 52-Week High (EBS) 4/13/11

Biotech/ Biodefense Sector Trading Alert 4/8/11

Biodefense Stocks/ Homeland Defense Stock Alert; Dynasil Corporation trading at $6.26, up 2.50 (66.49%) 3/23/11

Biodefense Stocks Snapshot 3/22/11

Can Pharmathene Go From $2 To $20? Seeking Alpha's James Altucher Investigates 10/15/10

Benzinga’s Top Pre-Market NASDAQ Gainers (UNCA, PRXI, TRBN, VECO) 8/13/10

Top 5 Small-Cap Stocks In The Biotechnology Industry With The Highest Return On Equity (OMPI, MRX, AOB, EBS, SSRX) 6/3/10

Financial Breakfast: Morning News Summary for January 9, 2012 1/9/12

UPDATE: Wedbush Lowers PT on EBS to $31 10/4/11

Wedbush Lowers PT on Emergent BioSolutions to $31 10/4/11

UPDATE: J.P. Morgan Raises PT on Emergent BioSolutions to $35 5/27/11

JP Morgan Raises PT On Emergent BioSolutions To $35 5/27/11

J.P. Morgan Comments On Uneventful 4Q10 Results For Emergent BioSolutions 3/11/11

Benzinga’s Top Downgrades (SWM , COGT, PRO, CNP, EBS) 5/6/10

J.P.Morgan’s View on Emergent BioSolutions Inc. (NYSE: EBS) 12/4/09

Trade EBS
NOW!

Partner Headlines

Company News for October 7, 2011 - Corporate Summary 10/7/11

9 Health Care Stocks With 100% Buy Ratings 5/5/11

Emergent BioSolutions Inc. Reports Operating Results (10-Q)

Press Releases

Red Hat Introduces Virtual Storage Appliance for Amazon Web Services 2/7/12 Business Wire Story

Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2012 1/30/12 Business Wire Story

EXFO Brings Unmatched Cloud and Mobile Backhaul Service Reliability with EtherSAM Burst Testing 1/27/12 Newswire Story

Starboard Value Delivers Letter to CEO and Board of Directors of Progress Software 1/24/12 Newswire Story

East West Petroleum Provides Update on Romanian Exploration Program 1/23/12 Marketwire Story

Bally Technologies Delivers the Innovation Experience at ICE 2012 as the Company Celebrates Its 80-Year Anniversary 1/17/12 Business Wire Story

Emergent BioSolutions Provides Preliminary 2011 Financial Results and Provides Guidance for 2012 1/9/12 Business Wire Story

Progress Software Reports 2011 Fiscal Fourth Quarter and Year End Results 1/3/12 Business Wire Story

Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia 12/28/11 Business Wire Story

Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott 12/28/11 Business Wire Story

Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO, Remain as Executive Chairman of the Board of Directors Focused on Corporate Strategy and M&A Opportunities 12/21/11 Business Wire Story

Allot and Korea Telecom set to Boost Internet Experience for Students 12/19/11 Newswire Story

Get the latest EBS stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Emergent Biosolutions stock price.

Emergent Biosolutions by YCharts

Emergent Biosolutions (EBS) 17.39 0.03

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On EBS

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social